Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Disease management--constructing optimal NRTI-based combinations: past, present, and future.

× No keyword cloud information.

58 in total

1. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.

Authors: J M Molina; G Chêne; F Ferchal; V Journot; I Pellegrin; M N Sombardier; C Rancinan; L Cotte; I Madelaine; T Debord; J M Decazes
Journal: J Infect Dis Date: 1999-08 Impact factor: 5.226

2. Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations.

Authors: L Sarmati; E Nicastri; S G Parisi; G D'Ettorre; P Narciso; G Mancino; I Gallo; V Abbadessa; N E Dalle; C Traina; V Vullo; M Andreoni
Journal: J Med Virol Date: 2001-12 Impact factor: 2.327

3. Update on Department of Health and Human Services guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.

Authors: J G Bartlett
Journal: Hopkins HIV Rep Date: 1999-07

4. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.

Authors: Roberto Manfredi; Leonardo Calza; Francesco Chiodo
Journal: AIDS Date: 2004-11-19 Impact factor: 4.177

5. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.

Authors: X Sáez-Llorens; R P Nelson; P Emmanuel; A Wiznia; C Mitchell; J A Church; J Sleasman; R Van Dyke; C G Richardson; A Cutrell; W Spreen; S Hetherington
Journal: Pediatrics Date: 2001-01 Impact factor: 7.124

6. Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.

Authors: A N Phillips; C Katlama; S Barton; S Vella; A Blaxhult; B Clotet; F D Goebel; B Hirschel; C Pedersen; J D Lundgren
Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1998-03-01

7. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

Authors: J S Montaner; P Reiss; D Cooper; S Vella; M Harris; B Conway; M A Wainberg; D Smith; P Robinson; D Hall; M Myers; J M Lange
Journal: JAMA Date: 1998-03-25 Impact factor: 56.272

8. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245

9. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.

Authors: Constance A Benson; Charles van der Horst; Anthony Lamarca; David W Haas; Cheryl K McDonald; Corklin R Steinhart; John Rublein; Joseph B Quinn; Elsa Mondou; Franck Rousseau
Journal: AIDS Date: 2004-11-19 Impact factor: 4.177

10. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors: A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal: Lancet Date: 1998-11-28 Impact factor: 79.321